Analysts Are Buzzing About This Potential Breakthrough in Cancer Therapy

Discover why Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is gaining Wall Street’s unanimous STRONG BUY rating. From earning FDA’s Fast Track Designation to showcasing at ASCO 2023, this small biotech firm is poised to make big strides in cancer treatment. Don’t miss your chance to learn more about their promising drug trials and a potential price target of $15.00.